These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 33171359)

  • 21. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
    Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
    Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trastuzumab with carboplatin/paclitaxel for treatment of advanced stage and recurrent uterine papillary serous carcinoma: A cost-effectiveness analysis.
    Batman S; Bohn J; Weisenberger MW; Hersh A; Bruegl A; Caughey A; Winter W
    Gynecol Oncol; 2021 Jan; 160(1):214-218. PubMed ID: 33393480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin-paclitaxel.
    Arrieta O; Anaya P; Morales-Oyarvide V; Ramírez-Tirado LA; Polanco AC
    Eur J Health Econ; 2016 Sep; 17(7):855-63. PubMed ID: 26338546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of Paclitaxel + Ramucirumab Combination Therapy for Advanced Gastric Cancer Progressing After First-line Chemotherapy in Japan.
    Saito S; Muneoka Y; Ishikawa T; Akazawa K
    Clin Ther; 2017 Dec; 39(12):2380-2388. PubMed ID: 29175097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness analysis of dostarlimab plus carboplatin-paclitaxel as first-line treatment for advanced endometrial cancer.
    You M; Zeng X; Zhang J; Huang Y; Zhang Y; Cai Z; Hu Y
    Front Immunol; 2023; 14():1267322. PubMed ID: 37731489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Budget impact of dostarlimab plus carboplatin-paclitaxel for primary advanced or recurrent endometrial cancer from a third-party US payer perspective.
    Lubinga SJ; Walder L; Burton M; Shen Q
    J Med Econ; 2024; 27(1):1212-1221. PubMed ID: 39254489
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer.
    Thongprasert S; Permsuwan U; Ruengorn C; Charoentum C; Chewaskulyong B
    Asia Pac J Clin Oncol; 2011 Dec; 7(4):369-75. PubMed ID: 22151987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Cost-Effectiveness of Bevacizumab in Advanced Ovarian Cancer Using Evidence from the ICON7 Trial.
    Hinde S; Epstein D; Cook A; Embleton A; Perren T; Sculpher M
    Value Health; 2016 Jun; 19(4):431-9. PubMed ID: 27325335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer.
    Lam SW; Wai M; Lau JE; McNamara M; Earl M; Udeh B
    Pharmacotherapy; 2017 Jan; 37(1):94-103. PubMed ID: 27870079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer.
    von Pawel J; Spigel DR; Ervin T; Losonczy G; Barlesi F; Juhász E; Anderson M; McCall B; Wakshull E; Hegde P; Ye W; Chen D; Chang I; Rhee I; Reck M
    Oncologist; 2018 Jun; 23(6):654-e58. PubMed ID: 29438092
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost Analyses in the US and Japan: A Cross-Country Comparative Analysis Applied to the PRONOUNCE Trial in Non-Squamous Non-Small Cell Lung Cancer.
    Hess LM; Rajan N; Winfree K; Davey P; Ball M; Knox H; Graham C
    Adv Ther; 2015 Dec; 32(12):1248-62. PubMed ID: 26650816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer.
    Franken MD; van Rooijen EM; May AM; Koffijberg H; van Tinteren H; Mol L; Ten Tije AJ; Creemers GJ; van der Velden AMT; Tanis BC; Uyl-de Groot CA; Punt CJA; Koopman M; van Oijen MGH
    Eur J Cancer; 2017 Apr; 75():204-212. PubMed ID: 28237866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis.
    Cohn DE; Kim KH; Resnick KE; O'Malley DM; Straughn JM
    J Clin Oncol; 2011 Apr; 29(10):1247-51. PubMed ID: 21383297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer.
    Young M; Plosker GL
    Pharmacoeconomics; 2001; 19(12):1227-59. PubMed ID: 11772158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bevacizumab in treatment of high-risk ovarian cancer--a cost-effectiveness analysis.
    Chan JK; Herzog TJ; Hu L; Monk BJ; Kiet T; Blansit K; Kapp DS; Yu X
    Oncologist; 2014 May; 19(5):523-7. PubMed ID: 24721817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
    Wu B; Chen H; Shen J; Ye M
    Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A phase II study of carboplatin plus weekly paclitaxel with bevacizumab for elderly patients with non-squamous non-small-cell lung cancer (NEJ016).
    Miura S; Maemondo M; Iwashima A; Harada T; Sugawara S; Kobayashi K; Inoue A; Nakagawa T; Takiguchi Y; Watanabe H; Ishida T; Terada M; Kagamu H; Gemma A; Yoshizawa H
    Invest New Drugs; 2017 Apr; 35(2):227-234. PubMed ID: 28150074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer.
    Montero AJ; Avancha K; Glück S; Lopes G
    Breast Cancer Res Treat; 2012 Apr; 132(2):747-51. PubMed ID: 22200867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US.
    Insinga RP; Vanness DJ; Feliciano JL; Vandormael K; Traore S; Ejzykowicz F; Burke T
    Curr Med Res Opin; 2019 Jul; 35(7):1241-1256. PubMed ID: 30649973
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.